+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Blepharitis - Pipeline Review, H2 2019

  • ID: 4866598
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 59 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Aerie Pharmaceuticals Inc
  • Azura Ophthalmics Ltd
  • Hovione FarmaCiencia SA
  • InSite Vision Inc
  • Merck & Co Inc
  • NicOx SA
  • MORE
Blepharitis - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Blepharitis - Pipeline Review, H2 2019, provides an overview of the Blepharitis (Ophthalmology) pipeline landscape.

Blepharitis is an inflammation of the eyelids, usually caused by an excess growth of bacteria that is ordinarily found on the skin, blockage of the eyelid's oil glands, and occasionally allergies. Blepharitis signs and symptoms include watery eyes, red eyes, itchy eyelids, sensitivity to light. Treatment includes antibiotics, lubricating eye drops and steroid eye drops or ointments.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Blepharitis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Blepharitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Blepharitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Blepharitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 2, 2 and 8 respectively.

Blepharitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Blepharitis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Blepharitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Blepharitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Blepharitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Blepharitis (Ophthalmology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Blepharitis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Blepharitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Aerie Pharmaceuticals Inc
  • Azura Ophthalmics Ltd
  • Hovione FarmaCiencia SA
  • InSite Vision Inc
  • Merck & Co Inc
  • NicOx SA
  • MORE
Introduction
Report Coverage
Blepharitis - Overview
Blepharitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Blepharitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Blepharitis - Companies Involved in Therapeutics Development
Aerie Pharmaceuticals Inc
Azura Ophthalmics Ltd
Formosa Pharmaceuticals Inc
Hovione FarmaCiencia SA
InSite Vision Inc
Merck & Co Inc
NicOx SA
Novaliq GmbH
Premark Pharma GmbH
Quorum Innovations LLC
Surface Pharmaceuticals Inc
Blepharitis - Drug Profiles
(doxycycline + omega 3 fatty acid) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APP-13002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZRBL-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZRBL-008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fluticasone propionate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HY-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISV-305 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOV-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PMP-2207 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Qi-402 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Dry Eye and Meibomian Blepharitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
solithromycin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Blepharitis - Dormant Projects
Blepharitis - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Table 1: Number of Products under Development for Blepharitis, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Products under Development by Companies, H2 2019
Table 4: Number of Products by Stage and Target, H2 2019
Table 5: Number of Products by Stage and Mechanism of Action, H2 2019
Table 6: Number of Products by Stage and Route of Administration, H2 2019
Table 7: Number of Products by Stage and Molecule Type, H2 2019
Table 8: Blepharitis - Pipeline by Aerie Pharmaceuticals Inc, H2 2019
Table 9: Blepharitis - Pipeline by Azura Ophthalmics Ltd, H2 2019
Table 10: Blepharitis - Pipeline by Formosa Pharmaceuticals Inc, H2 2019
Table 11: Blepharitis - Pipeline by Hovione FarmaCiencia SA, H2 2019
Table 12: Blepharitis - Pipeline by InSite Vision Inc, H2 2019
Table 13: Blepharitis - Pipeline by Merck & Co Inc, H2 2019
Table 14: Blepharitis - Pipeline by NicOx SA, H2 2019
Table 15: Blepharitis - Pipeline by Novaliq GmbH, H2 2019
Table 16: Blepharitis - Pipeline by Premark Pharma GmbH, H2 2019
Table 17: Blepharitis - Pipeline by Quorum Innovations LLC, H2 2019
Table 18: Blepharitis - Pipeline by Surface Pharmaceuticals Inc, H2 2019
Table 19: Blepharitis - Dormant Projects, H2 2019

List of Figures
Figure 1: Number of Products under Development for Blepharitis, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products by Targets, H2 2019
Figure 4: Number of Products by Stage and Top 10 Targets, H2 2019
Figure 5: Number of Products by Mechanism of Actions, H2 2019
Figure 6: Number of Products by Stage and Mechanism of Actions, H2 2019
Figure 7: Number of Products by Routes of Administration, H2 2019
Figure 8: Number of Products by Stage and Routes of Administration, H2 2019
Figure 9: Number of Products by Molecule Types, H2 2019
Figure 10: Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Aerie Pharmaceuticals Inc
  • Azura Ophthalmics Ltd
  • Formosa Pharmaceuticals Inc
  • Hovione FarmaCiencia SA
  • InSite Vision Inc
  • Merck & Co Inc
  • NicOx SA
  • Novaliq GmbH
  • Premark Pharma GmbH
  • Quorum Innovations LLC
  • Surface Pharmaceuticals Inc
Note: Product cover images may vary from those shown
Adroll
adroll